Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-5-3
|
| pubmed:abstractText |
The outcome of two different alternating regimens of chemotherapy was investigated in a prospective controlled trial in limited-stage small-cell lung cancer (SCLC). Both regimens comprised cyclophosphamide, lomustine, vincristine, methotrexate, doxorubicin and etoposide administered in different schedules. The investigative regimen (B) included simultaneous administration of cyclophosphamide + lomustine alternating with cyclophosphamide + doxorubicin, and with doxorubicin + lomustine. The hypothetical superiority of this regimen was based on data from experimental animal tumors suggesting potentiated efficacy of the three specific combinations. A total of 234 patients were included, and 113 vs 108 patients were eligible. Median survival in both groups was 48 weeks (p = 0.89). Complete remissions were observed in 36/101 and in 42/99 patients evaluable for response. There was no significant difference in response duration. At restaging after 18 months of chemotherapy 27 patients (16%) and 22 patients (16%), respectively, were free of disease. Six patients, three in each arm, are still alive, 8+ to 10.5+ years after diagnosis. Scheduled doses of the six agents were the same in the two regimens except for a 30% reduction of every second dose of cyclophosphamide in regimen B. Nevertheless, regimen B resulted in significantly more leukopenic patients, septicemic episodes, and blood transfusions, and the dosage of etoposide was more often reduced in arm B than in arm A. The increased toxicity was not associated with improved treatment results.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Lomustine,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
41-6
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1848996-Adult,
pubmed-meshheading:1848996-Aged,
pubmed-meshheading:1848996-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1848996-Brain Neoplasms,
pubmed-meshheading:1848996-Carcinoma, Small Cell,
pubmed-meshheading:1848996-Cyclophosphamide,
pubmed-meshheading:1848996-Doxorubicin,
pubmed-meshheading:1848996-Drug Administration Schedule,
pubmed-meshheading:1848996-Etoposide,
pubmed-meshheading:1848996-Female,
pubmed-meshheading:1848996-Hematologic Diseases,
pubmed-meshheading:1848996-Humans,
pubmed-meshheading:1848996-Lomustine,
pubmed-meshheading:1848996-Lung Neoplasms,
pubmed-meshheading:1848996-Male,
pubmed-meshheading:1848996-Methotrexate,
pubmed-meshheading:1848996-Middle Aged,
pubmed-meshheading:1848996-Neoplasm Staging,
pubmed-meshheading:1848996-Prospective Studies,
pubmed-meshheading:1848996-Recurrence,
pubmed-meshheading:1848996-Remission Induction,
pubmed-meshheading:1848996-Survival Rate,
pubmed-meshheading:1848996-Vincristine
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
|
| pubmed:affiliation |
Department of Oncology, Finsen Institute/Rigshospitalet, Copenhagen, Denmark.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|